ECONOMIC EVALUATION OF TRASTUZUMAB FOR THE ADJUVANT TREATMENT OF HER2 POSITIVE EARLY BREAST CANCER IN THE NETHERLANDS

被引：0
|
作者：
Essers, B. A. [1 ]
Tjan, Heijnen, V [1 ]
Severens, J. L. [1 ]
Novak, A. [2 ]
Oron, U. [3 ]
Pompen, M. [4 ]
Joore, M. A. [1 ]
机构：
[1] Univ Hosp Maastricht, Maastricht, Netherlands
[2] Anovak Serv, Apeldoorn, Netherlands
[3] Roche, Woerden, Netherlands
[4] Roche Netherland BV, Woerden, Netherlands
来源：
VALUE IN HEALTH | 2008年 / 11卷 / 06期
关键词：
D O I：
10.1016/S1098-3015(10)66577-1
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A472 / A472
页数：1
相关论文
共 50 条
  • [41] Long-term trastuzumab treatment in HER2 positive metastatic breast cancer
    Calamac, M.
    Minic, I.
    Tomasevic, Z.
    Oblakovic-Babic, J.
    Serovic, K.
    Djurmez, O.
    Dimitrijevic, M.
    Bozovic-Spasojevic, I.
    BREAST, 2021, 56 : S82 - S83
  • [42] An evaluation of the societal costs and benefits of adjuvant trastuzumab in the treatment of early HER2neu-positive breast cancer in Singapore.
    Lopes, G. D.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [43] Impact of adjuvant trastuzumab (AT) on survival in metastatic (M1) her2 positive breast cancer
    Lohrisch, C.
    Speers, C.
    Francl, M.
    Tyldesley, S.
    CANCER RESEARCH, 2013, 73
  • [44] Comparing Adjuvant 6 Months of Trastuzumab to the Standard 12 Months in Her2 Positive Breast Cancer
    EL Hagrasy, Seham
    Fahmy, Reham Safwat
    Fayed, Alaa
    Tantawy, Yousra
    LATIN AMERICAN JOURNAL OF PHARMACY, 2023, 42 (03): : 575 - 582
  • [45] Economic evaluation of adjuvant trastuzumab therapy for HER2-positive early-stage breast cancer: systematic review and quality assessment
    Genuino, Anne Julienne
    Gloria, Mac Ardy Junio
    Chaikledkaew, Usa
    Reungwetwattana, Thanyanan
    Thakkinstian, Ammarin
    EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2021, 21 (05) : 1001 - 1010
  • [46] Adjuvant Trastuzumab in HER2-Positive Breast Cancer REPLY
    Slamon, Dennis J.
    Buyse, Marc
    Press, Michael F.
    NEW ENGLAND JOURNAL OF MEDICINE, 2012, 366 (07): : 663 - 665
  • [47] Prevalence and management of HER2/neu-positive early breast cancer in a single institution following availability of adjuvant trastuzumab
    Chan, A.
    McGregor, S. R.
    INTERNAL MEDICINE JOURNAL, 2012, 42 (03) : 267 - 274
  • [48] Costeffectiveness analysis of adjuvant trastuzumab for HER-2 positive early breast cancer in Taiwan
    Chao, T. Y.
    Chen, S. C.
    Chang, K. J.
    Chang, H. K.
    Chen, D. R.
    Hou, M. F.
    Hsieh, R. K.
    Huang, W. T.
    Tseng, L. M.
    Wang, H. C.
    Yang, L.
    Cirrincione, A.
    VALUE IN HEALTH, 2007, 10 (06) : A327 - A327
  • [49] A COST-EFFECTIVENESS ANALYSIS OF ADJUVANT TRASTUZUMAB REGIMENS IN EARLY HER2/NEU-POSITIVE BREAST CANCER IN COLOMBIA
    Buendia Rodriguez, J. A.
    Vallejos, C.
    VALUE IN HEALTH, 2011, 14 (07) : A449 - A449
  • [50] The Effect of Adding Pertuzumab to Adjuvant Trastuzumab in Early HER2-Positive Breast Cancer
    Al-Azawi, Ahmed
    Hneua, Riyadh Abd-Alrasool
    Hameed, Rana Majeed
    Hassan, Duha Maithem
    JOURNAL OF CONTEMPORARY MEDICAL SCIENCES, 2023, 9 (03): : 197 - 200
12345